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The epidermal serine proteinase inhibitor SKALP
(also known as elafin), directed against human leuko-
cyte elastase and proteinase 3, is strongly induced in
suprabasal keratinocytes during inflammation. The
presence of SKALP/elafin in urine has been demon-
strated for several inflammatory skin disorders, such
as psoriasis, erythroderma, and erysipelas. In this
study we investigated whether SKALP/elafin levels in
serum and urine ofpsoriatic patients can be used as a
marker for disease activity during treatment. Patients
with severe chronic disabling psoriasis were treated
for 16 weeks with cyclosporin A, which resulted in a
marked clinical improvement as measured with the
PASI score. SKALP/elafin levels both in serum and
urine were determined with an enzyme-linked im-
e have recently shown that skin-derived
antileukoproteinase (SKALP), a serine pro-
teinase inhibitor virtually absent in normal
epidermis, is induced in lesional psoriatic
skin [1]. We found that SKALP, also known
as elafin [2,3J, is not specific for psoriasis, but can be considered as
one of the markers of the regenerative differentiation program that
is also found in other conditions such as wound healing [4,5] and
several inflammatory skin diseases [6]. SKALPI elafin is a strong
inhibitor of the leukocytic enzymes elastase [1] and proteinase-3
[7], and is putatively involved in the regulation of cutaneous
inflammation. In previous studies SKALPI elafin was described
biochemically [8J and characterized at the protein and DNA level
[9]. We established the cellular source and localization in psoriatic
epidermis [10], and we found that SKALP/elafin is differentially
expressed in human epidermal tumors [l1J. Recently we have been
able to assign the SKALPI elafin gene to chromosome region
20q12-q13 [12]. The gene has been given the approved name of
Protease Inhibitor, skin-derived (SKALP) and the symbol P13 in the
Genome Data Base of the HUGO nomenclature committee.
In psoriasis, SKALPI elafin is expressed in the upper spinous
layers of lesional skin [10]. We showed that SKALP/elafin as
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munosorbent assay (ELISA). Measurements were per-
formed at the start of the cyclosporin A treatment,
and after regular intervals up to 16 weeks. The results
indicate that 1) SKALP/elafin determination in serum
rather than in urine is the preferred method, because
the decrease in serum SKALP levels during therapy is
more pronounced and correlated better with the
clinical course of the patients; 2) SKALP/elafin levels
in serum decreased during cyclosporin A treatment
(p < 0.05); and 3) SKALP/elafin levels in serum cor-
relate with the PASI score (p < 0.01). We conclude
that SKALP/elafin measurement in serum of patients
with severe psoriasis provides a tool for monitoring
disease activity. Keywords: EliSAlproteinase inhibitorl
epidermis. J Invest Dermatol 104:189-193, 1995
expressed in cultured epidermal keratinocytes is translated as a
12.3-kDa protein. Cleavage of the signal peptide yields a 9.9-kDa
protein that is the major form found in cultured cells, as was
confirmed by purification and N-terrninal amino acid sequencing
[9]. The presence of a signal peptide suggests that SKALPI elafin is a
secreted protein. We indeed found that significant amounts ofbiolog-
ically active SKALPI elafin can be found in the urine of psoriatic
patients [13], a finding that was recently confmned by others [14]. In
urine ofhealthy individuals SKALP/eiafin was not detectable. Appar-
ently, once secreted in the epidermis, SKALPI elafin is able to reach
the circulation, and is subsequently cleared via the kidney. Although
we were then not able to measure SKALPI elafin in serum, this was a
likely route, because SKALPI elafin is a low-molecular-weight cat-
ionic protein that will easily cross basal membranes.
In the present study there were two objectives: first, we wanted
to develop an assay for SKALPI elafin assessment in serum of
psoriatic patients, and second we wanted to investigate if measure-
ment ofSKALPI elafm in urine and serum could be used as a marker
for disease activity during therapy. In our previous study, we used
a functional biochemical assay to measure SKALPI elafin in urine
[13]. However, in serum this is not possible due to interfering
factors. We therefore developed an enzyme-linked immunosorbent
assay (ELISA) that allows measurement of SY.ALP/elafin both in
serum and in urine. Using this ELISA we found that patients with
severe psoriasis during therapy with cyclosporin A (CyA) showed a
decrease of SKALPI elafin activity in serum that correlated with a
decrease in clinical scores (psoriasis area and severity index (PASI)
score). These findings suggest that SKALPI elafin can be used as a
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marker for disease activity and can be used as a quantitative 
measure to monitor therapeutic effects. 
MATERIALS AND METHODS 
Chemicals Tween-20 was obtained from Merck, Schuchardt, Hohen-
brunn bei Munich, Germany, and bovine serum albumin (BSA) from 
Organon Teknika, Boxtel, The Netherlands. Swine-anti-rabbit peroxidase 
was obtained from Dako, Copenhagen, Denmark, and o-phenyl-
enediamine.2HCI from Pierce, Rockford, IL. Microtiter plates (96 cells) for 
ELISA were obtained from Greiner, Alphen aid Rijn, The Netherlands. 
Recombinant SKALP/eiafin was a kind gift from Dr. Norman Russell, ICI 
Pharmaceuticals, UK. 
Subjects, Sample Collection and Preparation Fifteen healthy volun-
teers (5 male, 10 female , ages 2-79 years) took part in the experiments to 
study age or sex differencess in SKALP/elafin serum levels. For determina-
tion of circadian variation blood was drawn every 4 h during 24 h in a 
psoriatic patient and a healthy control. Six male patients (ages 36-64 years, 
mean age 48 years) with severe chronic disabling psoriasis participated. 
Patients had not used any systemic treatment for at least 4 weeks or local 
treatment for at least 1 week prior to the start ofCyA therapy. In all patients, 
initial dosage ofCyA was 3 mg/kg body weight; in two patients this dosage 
was increased up to 4 mg/kg body weight after 8 weeks of treatment. 
Before treatment, disease activity was evaluated and expressed using the 
PASI score. This scoring system estimates disease activity depending on 
erythema, infiltration, desquamation, and the area of the psoriatic skin that 
is affected [15]. At the start of CyA therapy , and after 2, 4, 8, 12, and 16 
weeks, samples of blood and urine were taken, and a PASI score as measure 
of disease activity. Samples of blood and urine were frozen and stored at 
- 20°C until measurement of SKALP / elafin. 
Anti-SKALPlElattn Serum Recombinant SKALP/elafin was used for 
immunization procedures as described before [8]. In short, a rabbit was 
immunized intracutaneously with recombinant SKALP/elafin that was 
crosslinked with glutaraldehyde and emulsified in Freund's complete adju-
vant. A booster with the same preparation was given after 2 weeks, and 4 
weeks later serum was collected via standard methods. Control (pre-
immune) serum was drawn before the immunization procedure. The 
specificity of the antiserum was validated as described before [8]. 
ELISA To measure SKALP/elafin concentrations in serum and urine of 
psoriatic patients, we used a competitive-type ELISA. Blood samples were 
taken, coagulated for 60 min at room temperature, and centrifuged at 450 
X g for 10 min . Serum was acidified to a final concentration of 0.05 N HCl, 
boiled for 2 min, and centrifuged for 60 min (2000 X g, 4°C). Urine was 
boiled for 2 min, cooled on ice for 30 min, and centrifuged for 15 min (2000 
X g, 4°C). Creatinine measurement was done before by an alkaline picrate 
determination with kinetic endpoint detection, and carried out with re-
agents from Boehringer Mannheim using a Hitachi 747 analyzer. Superna-
tants were taken for quantification of SKALP I elafin. 
The supernatants were mixed to contain 80% supernatant, 0 .1 M Tris, 
0.1 % Tween-20, 1% BSA, and rabbit anti-SKALP/elafin antiserum (1:9500 
diluted) , and incubated overnight. Microtiter plates (96 flat-bottom wells) 
were coated overnight with 50 ng/ml recombinant SKALP/elafin in 
phosphate-buffered saline (PBS). After washing of the plates with PBSI 
0.05% BSA, micro titer plates were blocked, probed with the test samples, 
and developed during 60 min with swine anti-rabbit peroxidase using 
o-phenylenediamine.2HCI as chromogenic substrate for 30 min. Human 
recombinant SKALPlelafin in PBS with 0.1% BSA was used as a standard: 
a calibration curve was made, using recombinant SKALP/elafin in the range 
of 0.6-80 ng/ml. The SKALP/eiafin concentrations in serum or urine 
samples were read from this curve. All ELISA steps were performed at 4°C, 
except development with o-phenylenediamine.2HCI, which was done at 
room temperature. Data were read with a Biorad ELISA-reader, and 
evaluated using the Excell spread sheet program. 
Statistical Analysis Regression analysis was performed to correlate 
SKALP I elafin levels in serum and urine with each other, with time of Cy A 
treatment, and with the disease activity as expressed in the PASI sco:e. 
Mean r (pearson moment product correlation) was obtained after Fisher-z 
transformation. 
RESULTS 
P ASI Score and Cy A Treatment All patients showed good 
clinical improvement during 16 weeks of treatment with CyA, and 
apart from slight gastrointestinal discomfort no complaints were 
reported. Mean PASI score was 20.0 (10.6-36.0) at the start of the 
treatment, and decreased to 3.4 (2.0-5.4) at week 16. In two 
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patients dosage of Cy A was increased at week 8 due to lack 01 
clinical progress. Using routine blood tests for liver and kidney 
functions, no side effects on these organs could be demonstrated; 
one patient showed hypertrichosis. Urine and blood samples of one 
of the patients could not be taken until 2 weeks after the start of the 
Cy A treatment. 
Sensitivity and Accuracy of the ELISA The ELISA we de-
veloped is of the competitive type, based on the displacement of a 
defined amount of recombinant SKALP I elafin by SKALP I elafin in 
the urine or serum samples. A calibration curve from which the 
sample values are read in the interval between 3-40 ng per ml is 
given in Fig 1. The detection limit is 3 ng/ ml. 
Experiments to check the recovery of recombinant SKALP I 
elafin added to normal human serum revealed that recovery is 
temperature dependent (not shown). When the ELISA was per-
formed at 4°C a recovery of 1 00% was found (Fig 2). Figure 2 also 
shows that a pool of normal human serum has a background level 
ofSKALP/elafin, which appeared to be about 9 ng/ml (intercept of 
the Y-axis). The standard deviation of measurements in quadrupli-
cate was within 10%. 
SKALPlElafin Measurement in Urine SKALP/elafin levels 
were expressed in ng/ml urine, and corrections for creatinine 
concentrations were made. SKALP I elafin levels in urine varied 
from 3 ng/ml up to more than 120 ng/ml (Fig 3). Five of six 
patients showed a clear decrease in urinary SKALP / elafin levels. 
One patient showed extremely low values of creatinine concentra-
tion, which had an enormous impact on correction for creatinine 
(Fig 3c); note that his serum level of SKALP I elafin decreased 
during treatment (Fig 4c). Decrease ofSKALP/elafin levels in urine 
during treatment was statistically significant (Fisher-z, p < 0.05). 
Urinary SKALP/elafin levels decreased, but were not found 
below 3 ng/ ml. Healthy controls do show a similar amount of 
SKALP/elafin in urine (data not shown), and 3-10 ng/ml may be 
regarded as a normal background level of SKALP I elafin in human 
unne. 
SKALPlElafin Measurement in Serum Serum levels for 
SKALP / elafin were measured in 15 healthy volunteers. No effect of 
age on SKALP/elafin levels was found (not shown). A small 
difference in SKALP/elafin serum levels (ng/ml) was found be-
tween male (14.6 ± 2.6) and female (8.5 ± 6.1). No circadian 
rhythm was observed (not shown). SKALP/elafin levels in psoriatic 
patients varied from 11 ng/ml up to more than 300 ng/ml (Fig 4). 
These levels significantly decreased during treatment with Cy A 
(Fisher-z, p < 0.05) and correlated well with clinical improvement 
as expressed in the PASI score (Fisher-z, p < 0.01). This decrease 
in SKALP/elafin level was found in the serum of all six patients. 
SKALP/elafin levels in serum were about sixfold higher than in 
urine, and levels in serum were positively correlated with levels in 
urine (Fisher-z, p < 0.01). 
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Figure 1. Calibration curve of recombinant SKALP/elattn. A 
sigmoid relationship between the ELISA signal and the SKALP I elafin 
concentration of the samples is found. The useful range for measurement of 
SKALP/elafin concentrations is between 3 and 40 ng/ml. 
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Figure 2. Mean values ± 2 SD of measurements in quadruplicate of 
three concentrations of recombinant SKALP/elafin in normal hu-
man serum. SD is 10%. The intercept with the Y-axis indicates that in 
humans a background serum level of SKALP / elafin appears to be present. 
This background level is about 9 ng/mt. 
DISCUSSION 
Increased amounts of SKALP I elafin have been demonstrated in 
urine of patients with psoriasis [13] and several other inflammatory 
skin diseases [14]. Because SKALP/elafin is barely detectable in 
normal skin and is strongly expressed in inflamed skin, we hypoth-
esized that the increase in urinary SKALP I elafin in psoriatics is 
derived from local production in skin. This would be in line with 
the fact that SKALP/elafin is a secreted molecule [16] and the 
notion that epidermis acts as a secretory organ as recently described 
[17 ,18]. However, no definitive proof could be given for the 
epidermal origin of urinary SKALP I elafin in psoriatic patients, 
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because SKALP I elafin could not be demonstrated in the interme-
diate compartments between epidermis and urine (i.e., dermis and 
blood). In our initial study we used a functional assay to measure 
SKALP I elafin, that could not be applied to serum, due to interfer-
ence by the overwhelming amount of other plasma-derived pro-
teinase inhibitors. 
Intraepidermal accumulation of PMN is an early event in the 
pathogenesis of the psoriatic lesion [19], and PMN-derived pro-
teinases were shown to degrade the dermo-epidermal junction in 
vitro [20] . This suggests that elastase may be involved in PMN 
migration and PMN-dependent tissue damage and may promote 
the inflammatory response. Several antipsoriatic therapies are 
known to interfere with this PMN migration, suggesting that they 
are involved in the downregulation of inflammation [21]. In 
addition to proteinases from inflammatory cells, keratinocyte-
derived proteinases such as plasminogen activator may act as a 
pro-inflammatory mediator in psoriatic skin [22]. Synthesis of 
proteinase inhibitors that counteract proteinases by forming inac-
tive complexes is one of the in vivo mechanisms to protect tissue 
against unwanted proteolysis [23]. These proteinase inhibitors may 
be present in plasma, or can be produced locally at the site of action 
[8,24,25]. Complexes between elastase and elastase inhibitors in 
serum, sputum, bronchoalveolar lavage, and urine have been 
described, the inhibitors being cd-PI [26-28], antileukoproteinase 
[29], or SKALP/elafin [13]. Levels of these complexes may be 
related to disease activity, and measurement may provide a tool for 
monitoring therapeutic result. Increased levels of complexes be-
tween elastase and inhibitors, but also of free elastase or free 
inhibitor, have been reported in lung cancer [30], neonatal systemic 
infection [31,32], adult respiratory distress syndrome [27,32], cer-
vical cancer [33,34], psoriasis, eczema, and other cutaneous dis or-
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Figure 3. SKALP/elafin levels in urine of six psoriatic patients (a-.I) during treatment with CyA. SKALP/elafin levels (ng/ml) are shown before 
(open. squares) and after correction for creatinine concentration (solid squares) . Decrease of SKALP/elafin levels in urine is statistically significant (Fisher z, 
p < 0.05). 
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Figure 4. SKALP/elafin levels in serum of six psoriatic patients (a-.D during treatment with CyA. Amount ofSKALP/elafin in serum is given in 
ng/ml (solid squares). Decrease ofSKALP/elafin levels in serum is statistically significant (Fisher z, p < 0.05). PASI scores at time of sampling are given (open 
squares). 
ders [35-37] , and these levels can be used as parameters for 
monotoring disease activity. 
In normal epidermis, anti-elastase activity is hardly detectable 
[1], although the presence of cd-PI and a2 macroglobulin in 
normal skin has been described [38,39]. Teleologically, it is plau-
sible that after a disturbance of the proteinase-antiproteinase bal-
ance in skin, resulting in an excess of elastase, SKALP I elafin is 
produced to limit proteolytic action of this leukocytic proteinase. 
After a period of proteolysis by elastase a rebalancing takes place, 
and SKALP/eiafin molecules may temporarily outnumber elastase 
molecules. Complexes are secreted in urine [13], but epidermic 
clearance via loss of scales that contain complexes may take place as 
well. Finally, restoration of normal homeostasis is followed by an 
off-switch of SKALP I elafin production by the epidermal cells. 
Using a competitive-type ELISA, we were able to demonstrate 
the presence of SKALP I elafin in serum of normal individuals and 
psoriatic patients. The assay was fOll.l1d to be reproducable and 
reasonably sensitive (detection limit 3 ng/ml). We found a back-
ground level of SKALP I elafin in serum of healthy controls and 
symptom-free psoriatic patients that is probably derived from the 
turnover in tissues where SKALP I elafin is constitutively expressed. 
We have recently completed a survey of SKALP I elafin in normal 
human epithelia (Alkemade et ai, manuscript in preparation) and 
found that the molecule is expressed in a limited number of normal 
tissues. This background level ofSKALP/elafin in serum negatively 
influences the sensitivity of the assay for detecting an increase in 
inflammatory skin diseases. 
In severe psoriatic patients with a large area of involved skin, 
serum levels are significantly higher than in healthy controls and 
symptom-free psoriatic patients. It is shown that during therapy 
with CyA, which is a potent antipsoriatic drug, serum levels 
gradually decrease and stabilize to a level that is still higher than in . 
normal controls. This decrease in SKALP I elafin levels correlates 
with the decrease in PASI scores, and we assume that the decrease 
in serum SKALP I elafin levels during therapy reflects the rate of 
normalization of the epidermis. The SKALP I elafin concentrations 
in serum were about sixfold higher than in urine, and the decrease I 
in serum during treatment was more impressive and correlated 
better with the clinical course. Therefore, determination of 
SKALP I elafin in serum rather than in urine was considered to be 
the method of preference. Because SKALP I elafin levels correlated 
well with the clinical state as represented by the PASI score, we 
conclude that SKALP I elafin measurement in serum of patients with 
severe psoriasis provides a tool for monitoring disease activity. 
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